Latest News

CELGENE CORPORATION: Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that Celgene has submitted a Biologics License Application (BLA) for luspatercept, an erythroid maturation agent, for the treatment of adult patients with very low to intermediate risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions and for the treatment of adult patients with beta-thalassemia-associated anemia who require RBC transfusions.

DAIICHI SANKYO, INC: EMA Validates Daiichi Sankyo’s Marketing Authorization Application for Pexidartinib for Treatment of Patients with TGCT, a Rare, Debilitating, Non-Malignant Tumor

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT), which is associated with severe morbidity or functional limitations, and which is not amenable to improvement with surgery.

CELGENE CORPORATION: Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis

Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for ozanimod for the treatment of adults with relapsing forms of multiple sclerosis (RMS). Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator, which binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5).

MERCK: Merck Increases Focus on Advanced Prostate Cancer, Expanding Immuno-Oncology Program with Three New Phase 3 Trials

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of interim data from the Phase 1b/2 KEYNOTE-365 umbrella trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with various agents for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

MERCK: Merck Highlights Breadth of Immuno-Oncology Research Program in Genitourinary Cancers at ASCO GU

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new combination and monotherapy data from the company’s broad immuno-oncology research program in genitourinary cancers – renal, prostate and bladder − will be presented at the 2019 Genitourinary Cancers Symposium (ASCO GU) in San Francisco from February 14-16.

DAIICHI SANKYO INC.: Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the first patient has been dosed in DESTINY-Breast04, a global pivotal phase 3 study evaluating the safety and efficacy of [fam-] trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody drug conjugate (ADC), in patients with HER2 low, unresectable and/or metastatic breast cancer previously treated with standard chemotherapy.

ASB RESOURCES: What's New in Business Intelligence for 2019

With the rising complexity of the business intelligence environment, the identification of trends is a key factor in effective decision-making.

MERCK: Merck Exercises Option for NGM Bio’s Investigational Insulin Sensitizer, NGM313, for the Treatment of NASH and Type 2 Diabetes

Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NGM Biopharmaceuticals, Inc. (NGM) today announced that Merck has exercised its option to license NGM313, an investigational monoclonal antibody agonist of the β-Klotho/FGFR1c receptor complex that is currently being evaluated for the treatment of nonalcoholic steatohepatitis (NASH) and type 2 diabetes.

OCEAN COUNTY: New App Puts Ocean County Parks and Recreation Information at Your Fingertips

Ocean County park sites and recreational activities can now be right at your fingertips thanks to a new app.

CORPORATE ESSENTIALS: How Corporate Catering Can Improve Your NJ or NYC Office

There are so many practical benefits to having corporate catering tend to your NJ or NYC company’s office refreshments and food needs.

DAIICHI SANKYO, INC: Daiichi Sankyo Initiates First Novel-Novel Combination Study of Two Investigational Agents within its AML Franchise in Patients with AML

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the first patient has been dosed in the first novel-novel combination study evaluating two investigational agents within its AML Franchise.

ABCO SYSTEMS: Conveyor System Maintenance

ABCO Systems offers conveyor maintenance and here is why.

MERCK: European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Adults with Resected Stage III Melanoma

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA, the company’s anti-PD-1 therapy, for the adjuvant treatment of adults with stage III melanoma and lymph node involvement who have undergone complete resection.

BD: BD Announces Completion Of Enterprise Level Cybersecurity Assessment From UL

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the completion of an enterprise level cybersecurity assessment from UL.

CELGENE CORPORATION: Celgene Corporation Announces Initial Phase 1/2 Liso-cel Data in Patients with Relapsed/Refractory CLL, Including Those with High-Risk Disease, Previously Treated with Ibrutinib, at ASH 2018

Celgene Corporation Announces Initial Phase 1/2 Liso-cel Data in Patients with Relapsed/Refractory CLL, Including Those with High-Risk Disease, Previously Treated with Ibrutinib, at ASH 2018

KONICA MINOLTA BUSINESS SOLUTIONS U.S.A. INC: Konica Minolta Strengthens Workplace Of The Future Offering With The Launch Of The Acuant i-Dentify 150 Scanner To Confirm Visitor Identity

Konica Minolta Business Solutions U.S.A., Inc. (Konica Minolta) today announced selection of the Acuant i-Dentify™ 150 Scanner, with Wintech’s ID Scan & Validate Subscription Plug-In, to complement the ALICE® Receptionist visitor management system.

Metro Business Network